Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.60 |
| ▸ | MAPT | P10636 | 12/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.60 |
| ▸ | HPGD | P15428 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500340 | 0.87 | PTPRC (0.58) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL15199361 | 0.85 | PTPRC (0.47) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL4055676 | 0.79 | ALDH1A1 (0.66) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL5449075 | 0.78 | CFTR (0.66) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL6315716 | 0.78 | CXCR2 (0.54) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL3495630 | 0.78 | MAPT (0.67) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL3761338 | 0.78 | HSD17B10 (0.67) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL135906 | 0.77 | TDP1 (0.50) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL8290653 | 0.76 | CFTR (0.67) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL5445117 | 0.76 | PTPRC (0.65) | ALDH1A1MAPTKDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| EP-3486246-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | Galapagos N.V. (BE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3486246-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | Galapagos N.V. (BE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3030568-B1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2018-09-19 | — | — | EP | disclosed |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| WO-2008003452-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. ORGANON (NL) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003452-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. ORGANON (NL) | 2008-01-10 | — | — | WO | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | CFTR, ABCB11, PKD1 | ALDH1A1 340/4885MAPT 4868/4885KDM4E 3244/4885 |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | ALDH1A1 506/4885MAPT 4880/4885KDM4E 3480/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | ALDH1A1 1153/4885MAPT 21/4885KDM4E 3417/4885 |
| US-20080255086-A1 | Heterocyclic Derivatives | GRIN2C, GRIN3A, GRIN1 | ALDH1A1 453/4885MAPT 449/4885KDM4E 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.